Treatment of age-related macular degeneration

Clinical and Experimental Optometry

Volumn 88, Issue 5, 2005, Pages 322-334

  Bylsma, Guy W ^a   Guymer, Robyn H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CENTRE FOR EYE RESEARCH AUSTRALIA   (Australia)

Author keywords

Macular degeneration; Treatment

Indexed keywords

PHOTOSENSITIZING AGENT;

ANIMAL; HUMAN; HYPERTHERMIC THERAPY; LASER COAGULATION; PHOTOCHEMOTHERAPY; PROGNOSIS; RETINA MACULA DEGENERATION; REVIEW; TREATMENT OUTCOME;

ANIMALS; HUMANS; HYPERTHERMIA, INDUCED; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33644685883     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2005.tb06716.x     Document Type: Review

References (133)

1. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 2001;108:960-967. (Pubitemid 32374254)
2. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:357-364. (Pubitemid 26085889)
3. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-191.
4. Bressler NM, Bressler SB, Fine SL. Agerelated macular degeneration. Surv Ophthalmol 1988;32:375-413.
5. Weih LM, Van Newkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000;118:264-269.
6. Access Economics. Clear insight. The economic impact and cost of visual loss in Australia. Melbourne. 2004.
7. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R et al. An international classification and grading system for age-related maculopathy and agerelated macular degeneration. Surv Ophthalmol 1995;39:367-374.
8. Steinmetz RL, Haimovici R, Jubb C, Fitzke FW, Bird AC. Symptomatic abnormalities of dark adaptation in patients with agerelated bruch's membrane change. Br J Ophthalmol 1993;77:549-554.
9. Ferris FL, Fine SL, Hyman L. Agerelated macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
10. Landy J, Brown GC. Update on photodynamic therapy. Curr Opin Ophthalmol 2003;14:163-168.
11. Macular Photocoagulation Study Group Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-509.
12. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114.
13. Macular Photocoagulation Study Group Occult choroidal neovascularization. Influence on visual outcome in patients with agerelated macular degeneration. Arch Ophthalmol 1996;114:400-412.
14. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1232-1241.
15. Freund KB, Yannuzzi LA, Sorenson JA. Agerelated macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:786-791.
16. Busbee BG, Brown MM, Brown GC, Sharma S. CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003;23:279-287
17. Ruiz-Moreno JM, Montero JA. Sequential combined therapy for treatment of choroidal neovascularization in age-related macular degeneration: Photodynamic therapy and thermal laser photocoagulation. Eur J Ophthalmol 2003;13:681-686.
18. Ufret-Vincenty RL, Miller JW, Gragoudas ES. Photosensitizers in photodynamic therapy of choroidal neovascularization. Int Ophthalmol Clin 2004;44:63-80.
19. Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S, Bartz-Schmidt KU. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 2004;88:207-211. (Pubitemid 38142088)
20. Moshfeghi DM, Kaiser PK, Grossniklaus HE, Sternberg P Jr, Sears JE, Johnson MW, Ratliff N, Branco A, Blumenkranz MS, Lewis H. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-350.
21. Flower RW. Experimental studies of indocyanine green dye-enhanced photocoagulation of choroidal neovascularization feeder vessels. Am J Ophthalmol 2000;129:501-512.
22. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004;138:803-808.
23. Grisanti S, Tatar O, Canbek S, Lafaut BA, Gelisken F, Inhoffen W, Szurman P, Aisenbrey S, Oficjalska-Mlynczak J, Bartz-Schmidt KU. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 2004;137:914-923.
24. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report No 1. Arch Ophthalmol 1999;117:1329-1345.
25. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
26. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004;111:931-939.
27. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials-TAP report no. 5. Arch Ophthalmol 2002;120:1307-1314. (Pubitemid 36105436)
28. Essex RW, Qureshi SH, Cain MS, Harper CA, Guymer RH. Photodynamic therapy in practice: A review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital. Clin Exp Ophthalmol 2003;31:476-481.
29. Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation-'beyond the TAP study'. Eye 2004;18:809-813.
30. Sharma S, Bakal J, Oliver-Fernandez A, Blair J. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: Results of an effectiveness study. Arch Ophthalmol 2004;122:853-856.
31. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Twoyear results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin In Photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
32. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-696.
33. Kaiser RS, Berger JW, Williams GA, Tolentino MJ, Maguire AM, Alexander J, Madjarov B, Margherio RM. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina 2002;22:683-690.
34. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110:400-405. (Pubitemid 36184347)
35. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
36. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
37. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age-related macular degeneration. Br J Ophthalmol 2004;88:982-987.
38. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004;122:1002-1011.
39. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
40. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304. (Pubitemid 40202568)
41. Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516.
42. Barouch FC, Miller JW. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin 2004;44:23-32.
43. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
44. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann RO. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-428.
45. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis A P. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828.
46. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001;108:705-710.
47. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;8:119-126.
48. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934.
49. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
50. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162.
51. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-144.
52. Csaky K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: Promises and pitfalls. Ophthalmology 2003;110:879-881.
53. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 2004;14:237-248.
54. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (fgf-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 2002;88:834-842.
55. Yourey PA, Gohari S, Su JL, Alderson RF. Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 2000;20:6781-6788.
56. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
57. Adamis A. Two-year data for Macugen. In: American Academy of Ophthalmology Annual Meeting, Retina Subspecialty Day; 2004; Luisiana, New Orleans: 2004.
58. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD) : Interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23.
59. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283-290.
60. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna S P, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelve-month clinical outcomes. Ophthalmology 2003;110:2372-2383.
61. Alcon Incorporated. Alcon announces anecortave acetate clinical results. http://invest.alconinc.com/phoenix/phoenix.zhtml?c-130946&p- irolnewsArticle&ID-630541&highlight. Accessed 17 May 2005.
62. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: Etiology, pathogenesis and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.
63. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
64. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-383.
65. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-298.
66. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-281.
67. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
68. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529.
69. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative agerelated macular degeneration. Br J Ophthalmol 2003;87:462-468. (Pubitemid 36399037)
70. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003;121:667-673.
71. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
72. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-1055. (Pubitemid 40040030)
73. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 2004;88:344-347.
74. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-222. (Pubitemid 38176489)
75. Jonas JB, Kreissig I, Degenring R. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:873-874.
76. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: A review of experimental treatments. Surv Ophthalmol 1998;43:134-146.
77. Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998;236:321-325.
78. Char DH, Irvine AI, Posner MD, Quivey J, Phillips TL, Kroll S. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 1999;127:574-578.
79. Ciulla TA, Danis RP, Klein SB, Malinovsky VE, Soni PS, Pratt LM, Pugh NO, Morphis JG, Bloch C, Cameron J. Proton therapy for exudative age-related macular degeneration: A randomized, sham-controlled clinical trial. Am J Ophthalmol 2002;134:905-906.
80. Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: A randomized clinical trial. Am J Ophthalmol 2002;133:521-529. (Pubitemid 34258061)
81. Kobayashi H, Kobayashi K. Age-related macular degeneration: Long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 2000;130:617-635.
82. Anonymous. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD study). Radiation therapy for age-related macular degeneration. Ophthalmology 1999;106:2239-2247.
83. Marcus DM, Sheils W, Johnson MH, McIntosh SB, Leibach DB, Maguire A, Alexander J, Samy CN. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: One-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2001;119:171-180.
84. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, Owens SL, Hall V, Houston RF, McCulloch DW, Plowman N. Visual outcomes in the subfoveal radiotherapy study: A randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 2002;120:1029-1038.
85. Marcus DM, Peskin E, Maguire M, Weissgold D, Alexander J, Fine S, Followill D; AMDRT Research Group. The agerelated macular degeneration radiotherapy trial (AMDRT) : One year results from a pilot study. Am J Ophthalmol 2004;138:818-828.
86. Desai V, Reichel E, Kroll AJ, Duker J, Pulaifito C. Transpupillary thermotherapy of subfoveal choroidal neovascularisation in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998;39(suppl):385.
87. Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, Redford M, Schwartz SD, Sternberg P Jr, Thomas MA, Wilson DJ; Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SST report no. 11. Ophthalmology 2004;111:1967-1980.
88. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, MacCumber MW, Marsh MJ, Redford M, Sternberg P Jr, Thomas MA, Williams GA; Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 2004;111:1993-2006.
89. Stanga PE, Kychenthal A, Fitzke FW, Halfyard AS, Chan R, Bird AC, Aylward GW. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology 2002;109:1492-1498.
90. Lappas A, Foerster AM, Weinberger AW, Coburger S, Schrage NF, Kirchhof B. Translocation of iris pigment epithelium in patients with exudative age-related macular degeneration: Long-term results. Graefes Arch Clin Exp Ophthalmol 2004;242:638-647.
91. Binder S, Stolba U, Krebs I, Kellner L, Jahn C, Feichtinger H, Povelka M, Frohner U, Kruger A, Hilgers RD, Krugluger W. Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: A pilot study. Am J Ophthalmol 2002;133:215-225.
92. Binder S, Krebs I, Hilgers RD, Abri A, Stolba U, Assadoulina A, Kellner L, Stanzel BV, Jahn C, Feichtinger H. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: A prospective trial. Invest Ophthalmol Vis Sci 2004;45:4151-4160.
93. Semkova I, Kreppel F, Welsandt G, Luther T, Kozlowski J, Janicki H, Kochanek S, Schraermeyer U. Autologous transplantation of genetically modified iris pigment epithelial cells: A promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci U S A 2002;99:13090-13095.
94. van Meurs JC, ter Averst E, Hofland LJ, van Hagen PM, Mooy CM, Baarsma GS, Kuijpers RW, Boks T, Stalmans P. Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes. Br J Ophthalmol 2004;88:110-113.
95. van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: Short-term follow-up. Am J Ophthalmol 2003;136:688-695.
96. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993;231:635-641. (Pubitemid 23342235)
97. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counterrotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313-325.
98. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-495.
99. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, Klein BE, Smith W, De Jong PT. Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents. Ophthalmology 2004;111:1280-1287.
100. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS). AREDS report no. 19. Ophthalmology 2005;112:533-539.
101. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
102. The Alpha-tocopherol, Beta carotene Cancer prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035.
103. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh J P, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-1155.
104. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000;852:274-278.
105. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002;287:47-54.
106. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatinniacin therapy in patients with coronary artery disease and low HDL. Arterioscl Thromb Vasc Biol 2001;21:1320-1326.
107. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR. Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res 2000;75:79-85.
108. Jampol LM. AREDS-two years later. Arch Ophthalmol 2003;121:1634-1636.
109. Bressler NM, Bressler SB, Congdon NG, Ferris FL, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM. Age-Related Eye Disease Study Research Group. Potential public health impact of agerelated eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624.
110. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age-related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004;88:450-454.
111. Trevithick J, Massel D, Robertson JM, Tomany S, Wall R. Model study of AREDS antioxidant supplementation of AMD compared to visudyne: A dominant strategy? Ophthalmic Epidemiol 2004;11:337-346.
112. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The veterans last study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75:216-230.
113. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. Arch Ophthalmol 1988;106:192-198.
114. Stur M, Tittl M, Reitner A, Meisinger V. Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:1225-1235.
115. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Visaline in the treatment of age-related macular degeneration: A pilot study. Ophthalmologica 1995;209:302-305.
116. Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ. Vitamin E supplementation and macular degeneration: Randomised controlled trial. BMJ 2002;325:11.
117. Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, Albanes D, Taylor P, Heinonen OP. Six-year supplementation with alpha-tocopherol and betacarotene and age-related maculopathy. Acta Ophthalmol Scand 1998;76:224-229.
118. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol 1973;90:206-217.
119. Rodanant N, Friberg TR, Cheng L, Aurora A, Bartsch D, Toyoguchi M, Corbin PS, El-Bradey MH, Freeman WR. Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative agerelated macular degeneration. Am J Ophthalmol 2002;134:577-585.
120. Scorolli L, Corazza D, Morara M, Vismara S, Lugaresi ML, Meduri RA. Argon laser vs. subthreshold infrared (810-nm) diode laser macular grid photocoagulation in nonexudative age-related macular degeneration. Can J Ophthalmol 2003;38:489-495.
121. Frennesson CI. Prophylactic laser treatment in early age-related maculopathy: An 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. Acta Ophthalmol Scand 2003;81:449-454.
122. Owens SL, Bunce C, Brannon AJ, Wormald R, Bird AC, Drusen Laser Study Group. Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: Results of an interim analysis. Eye 2003;17:623-627.
123. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: Updated findings from a pilot randomized clinical trial. Ophthalmology 2003;110:971-978.
124. Maguire M, Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-item National Eye Institute visual functioning questionnaire, and their associations in the complications of age-related macular degeneration prevention trial (CAPT). Ophthalmology 2004;111:1307-1316.
125. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA reductase inhibitors (statins) : Do they have a role in age-related macular degeneration? Surv Ophthalmol 2005;50:194-206.
126. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137:615-624.
127. Klein R, Klein BE, Jensen SC, Cruickshanks KJ, Lee KE, Danforth LG, Tomany SC. Medication use and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol 2001;119:1354-1359. (Pubitemid 32994881)
128. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: Cross sectional study. BMJ 2001;323:375-376.
129. McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk factors for agerelated maculopathy: The Visual Impairment Project. Arch Ophthalmol 2001;119:1455-1462.
130. McGwin G Jr, Owsley C, Curcio CA, Crain RJ. The association between statin use and age-related maculopathy. Br J Ophthalmol 2003;87:1121-1125.
131. van Leeuwen R, Tomany SC, Wang JJ, Klein R, Mitchell P, Hofman A, Klein BE, Vingerling JR, Cumming RG, de Jong PT. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology 2004;111:1169-1175.
132. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age-related maculopathy: Prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-256.
133. McGwin G Jr, Xie A, Owsley C. The use of cholesterol-lowering medications and agerelated macular degeneration. Ophthalmology 2005;112:488-494.